Recent TVGN News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/23/2024 09:04:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:02:28 PM
- Tevogen Bio Secures $6 Million Series C Preferred Stock Investment • GlobeNewswire Inc. • 08/22/2024 01:00:00 PM
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares • GlobeNewswire Inc. • 08/15/2024 04:17:01 PM
- Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares • GlobeNewswire Inc. • 08/15/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/14/2024 08:40:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:38:58 PM
- Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health • GlobeNewswire Inc. • 08/14/2024 01:00:00 PM
- Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities • GlobeNewswire Inc. • 08/09/2024 03:00:00 PM
- Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback • GlobeNewswire Inc. • 07/11/2024 04:21:21 PM
- Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian • GlobeNewswire Inc. • 07/10/2024 12:05:00 PM
- Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility • GlobeNewswire Inc. • 07/08/2024 08:07:16 PM
- Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities • GlobeNewswire Inc. • 06/26/2024 04:46:13 PM
- Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances • GlobeNewswire Inc. • 06/25/2024 12:05:00 PM
- Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference • GlobeNewswire Inc. • 06/18/2024 07:17:05 PM
- Tevogen Bio Set to Join Russell 3000® Index • GlobeNewswire Inc. • 06/12/2024 07:45:00 PM
- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts • GlobeNewswire Inc. • 06/11/2024 07:30:00 PM
- CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event • GlobeNewswire Inc. • 06/07/2024 07:32:04 PM
- Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event • GlobeNewswire Inc. • 06/06/2024 10:14:31 PM
- Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 • GlobeNewswire Inc. • 06/06/2024 07:52:26 PM
- Tevogen Bio Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives • GlobeNewswire Inc. • 05/16/2024 06:00:00 PM
- Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives • GlobeNewswire Inc. • 05/10/2024 09:40:49 PM
- Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives • GlobeNewswire Inc. • 05/01/2024 12:05:00 PM
- Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments • GlobeNewswire Inc. • 04/26/2024 01:23:59 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM